Satsuma Pharmaceuticals, Inc.

STSADelisted Jun 8, 2023

Industry: Pharmaceutical Preparations
SEC CIK: 0001692830

SEC filings (opens in a new tab)

Satsuma Pharmaceuticals, Inc. was delisted on Jun 8, 2023; its insiders filed their last Form 4 on Jun 12, 2023; 31 institutions reported holding it in 13F filings for Q1 2023, worth $12.7M in total; no superinvestor held it.

Q3 2022 vs. Q2 2022

How the institutions holding Satsuma Pharmaceuticals, Inc. changed between Q2 2022 and Q3 2022.

All holders in Q3 2022 All holders in Q2 2022

13F holders of STSA: Q2 2022 compared with Q3 2022
Measure	Q2 2022	Q3 2022	Change
Holders	32	41	+9
Shares	22.8M	24.4M	+1.68M (+7.4%)
Value	$94.2M	$146.7M	+$52.5M (+55.7%)

New holders (14)

Institutions that held Satsuma Pharmaceuticals, Inc. at the end of Q3 2022 but not at the end of Q2 2022.

Institutions new to STSA in Q3 2022
Institution	Shares	Value	% of portfolio
Driehaus Capital Management LLC	1,714,046	$10.3M	0.16%
EAM Investors, LLC	149,029	$894.0K	0.19%
Caption Management, LLC	90,000	$539.0K	0.09%
Simplex Trading, LLC	67,823	$406.0K	0.02%
Millennium Management LLC	62,116	$373.0K	0.00%
Bank of America Corp	18,495	$111.0K	0.00%
Bank of New York Mellon Corp	16,262	$98.0K	0.00%
Susquehanna International Group, LLP	12,050	$72.0K	0.00%
Marshall Wace, LLP	10,123	$61.0K	0.00%
Virtu Financial LLC	10,096	$61.0K	0.01%
Renaissance Technologies LLC	10,000	$60.0K	0.00%
Federated Hermes, Inc.	100	$1.00K	0.00%
Tower Research Capital LLC (TRC)	110	$1.00K	0.00%
BNP Paribas Arbitrage, SA	59	$354	0.00%

Sold out (5)

Institutions that held Satsuma Pharmaceuticals, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.

Institutions that sold out of STSA in Q3 2022
Institution	Shares, Q2 2022	Value, Q2 2022
Citadel Advisors LLC	150,954	$624.0K
JPMorgan Chase & Co	46,998	$195.0K
Norges Bank	17,700	$73.3K
Charles Schwab Investment Management Inc	12,319	$52.0K
Goldman Sachs Group Inc	10,109	$42.0K